Investigational drug · Phase 2
ENN0403
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Diabetic Macular Edema (DME).
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 5, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
3
Any phase or sponsor naming "ENN0403"
First trial start
2024
Dec 12, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ENN0403", any sponsor or status.
Conditions studied
As listed on its trial records.
- Diabetic Macular Edema (DME)
Approved drugs for the same conditions: Diabetic macular edema · Cardiovascular and metabolic · Ophthalmology
Largest trials
Live from ClinicalTrials.gov: studies naming "ENN0403" as an intervention, largest first.
- Efficacy and Safety of ENN0403 in Patients At High Risk for Acute Kidney Injury Following Elective Cardiac SurgeryPivotal-lookingStatus unknown
EnnovaBioIndustry
NCT06632613 · 200 participants (planned) · Start Nov 5, 2024 · Primary completion Feb 2026
Drug: ENN0403 capsules, low dose; ENN0403 capsules, high dose and 1 more · For: Cardiac Surgery Associated - Acute Kidney Injury
Sites: Shanghai, China
- A First-in-human Single Ascending Dose/Multiple Ascending Dose Study of ENN0403 in Healthy SubjectsCompleted
EnnovaBioIndustry
NCT05506540 · 69 participants · Start Feb 17, 2021 · Primary completion May 16, 2022
Drug: ENN0403 1mg; ENN0403 4mg and 8 more · For: Healthy
Sites: Adelaide, Australia
EnnovaBioIndustry
NCT06708260 · 60 participants · Start Dec 12, 2024 · Primary completion Aug 12, 2026
Drug: ENN0403, low dose; ENN0403, high dose · For: Diabetic Macular Edema (DME)
Sites: Shijiazhuang, China; Xingtai, China; Zhengzhou, China · 9 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Diabetic Macular Edema (DME)
- 4D-1503E10 vg, eyePhase 35 trials
4D Molecular Therapeutics · Neovascular Age-Related Macular Degeneration (nAMD), Diabetic Macular Edema (DME), Neovascular (Wet) Age-Related Macular Degeneration
- TiespectusEYE201, MK-8748Phase 35 trials
EyeBiotech Ltd. · Macular Degeneration, Age-Related Macular Degeneration, Choroidal Neovascularization
- EYP-1901Phase 34 trials
EyePoint Pharmaceuticals, Inc. · Diabetic Macular Edema, DME, Diabetic Macular Edema (DME)
- OLN324Phase 34 trials
Ollin Biosciences, Inc. · Diabetic Macular Edema (DME), Wet Age Related Macular Degeneration, Wet Age-related Macular Degeneration
- RemigromigEYE103, RestoretPhase 33 trials
EyeBiotech Ltd. · Diabetic Macular Edema (DME), Neovascular Age-Related Macular Degeneration (NVAMD), Branch Retinal Vein Occlusion (BRVO)
- BAT5906Phase 32 trials
Bio-Thera Solutions · Diabetic Macular Edema (DME), Neovascular (Wet) Age-related Macular Degeneration
- Tabirafusp tedromerKSI-501Phase 32 trials
Kodiak Sciences Inc · Diabetic Macular Edema (DME), Wet Age-related Macular Degeneration
- RC28-EPhase 31 trial
RemeGen Co., Ltd. · Diabetic Macular Edema (DME), wAMD
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.